These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30870877)

  • 21. Development of an effective topical liposomal formulation for localized analgesia and anti-inflammatory actions in the Complete Freund's Adjuvant rodent model of acute inflammatory pain.
    Iwaszkiewicz KS; Hua S
    Pain Physician; 2014; 17(6):E719-35. PubMed ID: 25415787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U; Kelley LK; Middleton JW; Gilpin NW
    Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical cannabinoid enhances topical morphine antinociception.
    Yesilyurt O; Dogrul A; Gul H; Seyrek M; Kusmez O; Ozkan Y; Yildiz O
    Pain; 2003 Sep; 105(1-2):303-8. PubMed ID: 14499448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.
    Abalo R; Chen C; Vera G; Fichna J; Thakur GA; López-Pérez AE; Makriyannis A; Martín-Fontelles MI; Storr M
    Neurogastroenterol Motil; 2015 Dec; 27(12):1721-35. PubMed ID: 26387676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat.
    Abalo R; Uranga JA; Pérez-García I; de Andrés R; Girón R; Vera G; López-Pérez AE; Martín-Fontelles MI
    Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 27686064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocannabinoids as physiological regulators of colonic propulsion in mice.
    Pinto L; Izzo AA; Cascio MG; Bisogno T; Hospodar-Scott K; Brown DR; Mascolo N; Di Marzo V; Capasso F
    Gastroenterology; 2002 Jul; 123(1):227-34. PubMed ID: 12105851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel simultaneous measurement method to assess the influence of intracerebroventricular obestatin on colonic motility and secretion in conscious rats.
    Chen CY; Doong ML; Li CP; Liaw WJ; Lee HF; Chang FY; Lin HC; Lee SD
    Peptides; 2010 Jun; 31(6):1113-7. PubMed ID: 20338205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.
    Paquette J; Olmstead MC
    Behav Pharmacol; 2005 Dec; 16(8):597-603. PubMed ID: 16286810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impacts of peripheral obestatin on colonic motility and secretion in conscious fed rats.
    Chen CY; Chien EJ; Chang FY; Lu CL; Luo JC; Lee SD
    Peptides; 2008 Sep; 29(9):1603-8. PubMed ID: 18565623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
    Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
    Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition.
    Hua S; Cabot PJ
    Pain Physician; 2013; 16(3):E199-216. PubMed ID: 23703419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice.
    Carai MA; Colombo G; Gessa GL; Yalamanchili R; Basavarajappa BS; Hungund BL
    Br J Pharmacol; 2006 Aug; 148(8):1043-50. PubMed ID: 16847440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.
    Maguire DR; France CP
    Psychopharmacology (Berl); 2018 Aug; 235(8):2357-2365. PubMed ID: 29860612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats.
    López-Gómez L; Díaz-Ruano S; Girón R; López-Pérez AE; Vera G; Herradón Pliego E; López-Miranda V; Nurgali K; Martín-Fontelles MI; Uranga JA; Abalo R
    Neurogastroenterol Motil; 2018 Nov; 30(11):e13399. PubMed ID: 29971865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of cannabinoid 2 receptor relieves colonic hypermotility in a rat model of irritable bowel syndrome.
    Lin M; Chen L; Xiao Y; Yu B
    Neurogastroenterol Motil; 2019 Jun; 31(6):e13555. PubMed ID: 30793435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
    Maguire DR; France CP
    Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Establishment and effect observation on three kinds of Ti-Xu with constipation rat models].
    Du LD; Ren Y; Niu TH; Wu GT; Wang ZW; Liu WZ; Shao J
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2017 Feb; 33(2):140-145. PubMed ID: 29931922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hydrogen sulphide on motility patterns in the rat colon.
    Gil V; Parsons S; Gallego D; Huizinga J; Jimenez M
    Br J Pharmacol; 2013 May; 169(1):34-50. PubMed ID: 23297830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio.
    Eiselt E; Côté J; Longpré JM; Blais V; Sarret P; Gendron L
    Eur J Pharmacol; 2019 Apr; 848():80-87. PubMed ID: 30707956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.